Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study by Sara Barbeito et al.
Barbeito et al. BMC Psychiatry 2013, 13:326
http://www.biomedcentral.com/1471-244X/13/326RESEARCH ARTICLE Open AccessCannabis use and involuntary admission may
mediate long-term adherence in first-episode
psychosis patients: a prospective longitudinal
study
Sara Barbeito1, Patricia Vega1, Sonia Ruiz de Azúa1,3, Margarita Saenz1, Mónica Martinez-Cengotitabengoa1,2,
Itxaso González-Ortega1,3, Cristina Bermudez1, Margarita Hernanz1, Blanca Fernández de Corres1
and Ana González-Pinto1,3,4*Abstract
Background: This study aimed to examine factors associated with treatment adherence in first-episode psychosis
(FEP) patients followed up over 8 years, especially involuntary first admission and stopping cannabis use.
Methods: This prospective, longitudinal study of FEP patients collected data on symptoms, adherence, functioning,
and substance use. Adherence to treatment was the main outcome variable and was categorized as ‘good’ or ‘bad’.
Cannabis use during follow-up was stratified as continued use, stopped use, and never used. Bivariate and logistic
regression models identified factors significantly associated with adherence and changes in adherence over the
8-year follow-up period.
Results: Of the 98 FEP patients analyzed at baseline, 57.1% had involuntary first admission, 74.4% bad adherence,
and 52% cannabis use. Good adherence at baseline was associated with Global Assessment of Functioning score
(p = 0.019), Hamilton Depression Rating Scale score (p = 0.017) and voluntary admission (p < 0.001). Adherence
patterns over 8 years included: 43.4% patients always bad, 26.1% always good, 25% improved from bad to good.
Among the improved adherence group, 95.7% had involuntary first admission and 38.9% stopped cannabis use. In
the subgroup of patients with bad adherence at baseline, involuntary first admission and quitting cannabis use
during follow up were associated with improved adherence.
Conclusions: The long-term association between treatment adherence and type of first admission and cannabis
use in FEP patients suggest targets for intervention to improve clinical outcomes.
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First-episode psychosis (FEP) patients often demonstrate
denial of illness, refusal to be admitted into a psychiatric
unit, and poor medication adherence. As many as 60%
of FEP patients have poor adherence to medication [1],
and 20% persistently refuse medication [2]. FEP patients
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reproduction in any medium, provided the oradmission (voluntary or involuntary) may be associated
with treatment adherence and with the severity and/or
prognosis of the disorder [3].
Factors influencing adherence in FEP patients have
been examined in only a few prospective longitudinal
studies and the findings have been inconsistent. Among
factors reported to have a negative effect on adherence are
greater symptom severity (positive symptoms, especially
delusions and paranoia), hostility, poorer cognitive func-
tioning, lower parental social class, less education, medica-
tion side-effects, longer duration of untreated psychosis,
substance abuse, alcohol consumption, and poor insightl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ist alliance has been associated with positive effects on
adherence [8].
Patient characteristics associated with involuntary first
admission include worse psychopathology (positive symp-
toms), suicidal behavior, aggressive behavior, lack of insight,
substance use, and worse functioning [3,9-11]. However,
outcome differences between patients admitted voluntarily
and involuntarily and the factors associated with these out-
comes have not been well studied. There is some evidence
that patients admitted involuntarily have poorer long-term
outcomes because they are less likely to use medication
and to engage with mental health services after hospital
discharge than patients admitted voluntarily [12]. In one
study of FEP patients, involuntary admission was an inde-
pendent predictor of medication adherence over 5 years of
follow-up [4]. Conversely, in another study, treatment ad-
herence, psychopathology and functioning at the 2-year
follow-up did not differ between FEP patients admitted
voluntarily and involuntarily [3]. Nevertheless, most pa-
tients admitted involuntarily eventually agree that forced
admission was necessary at the time and that their treat-
ment was beneficial, and these perceptions are associated
with better insight [13,14].
Substance use, especially cannabis use, is common
among patients with psychosis [15], and is associated with
worse clinical outcomes, including increased relapse rates
[16]. Reported rates of substance abuse in FEP patients
vary (ranging from 11% to 62%), and patients with persist-
ent substance use have an increased risk of relapse/re-
admission and poorer functional outcome than those who
stop using substances or who have never used them [17].
Cannabis use may be a risk factor for non-adherence or
discontinuation of treatment in FEP patients [18], and was
consistently associated with non-adherence in a systematic
review [16]. The long-term consequences of poor adher-
ence in FEP patients include more frequent episodes and
hospital readmissions, especially involuntary admissions
[13], and a higher risk of suicide [19]. Early identification
of factors that predict poor adherence and, consequently,
a worse course of illness would facilitate the early use of
beneficial interventions. Enhanced adherence in the first
few years of illness may improve medium- and long-
term outcomes [20]. Long-term studies in FEP patients
are needed.
The main aim of this prospective longitudinal study
was to identify factors associated with adherence to treat-
ment in FEP patients, with a particular focus on whether
the type of first hospitalization (voluntary versus involun-
tary), other baseline factors, and cannabis use over the
8 year follow-up period were important variables affecting
adherence. We also examined factors associated with the
change in adherence over 8 years of follow-up, and specif-
ically assessed whether the change in adherence forpatients with bad adherence at baseline was associated
with type of first hospitalization (voluntary versus involun-
tary) and change in cannabis use over 8 years of follow-up.
We hypothesized that (a) adherence in the long-term is
influenced by both the type of first hospitalization and
cannabis use during follow-up, and (b) FEP patients with
involuntary first admission and/or who stop using canna-
bis may have improved adherence in the long-term.
Methods
Patients and methods
Data were gathered on recent-onset FEP patients admit-
ted consecutively to a general hospital psychiatric ward
between 1997 and 1999, and who were all subsequently
followed-up over 8 years. The hospital provides psychi-
atric care to all inhabitants (approximately 300 000
people) of the catchment area of the city of Vitoria in the
Spanish Basque Country. As there are no other psychiatric
inpatient units in this area, the study sample is representa-
tive of FEP patients who need inpatient psychiatric care.
The study was approved by the Ethics Committee of Hos-
pital Santiago Apóstol and the participating patients were
enrolled after providing informed consent.
The FEP patients included in the study were aged 18–
65 years and met the DSM-IV criteria for schizophreni-
form disorder, schizoaffective disorder, schizophrenia,
delusional disorder, brief psychotic disorder, psychotic
disorder not otherwise specified (NOS), bipolar disorder
with psychotic features, or major depressive disorder
with psychotic features. Patients with substance-induced
psychotic disorders, mental retardation or organic brain
disorders were excluded from this study. The DSM-IV
axis I diagnosis was made using the Structured Clinical
Interview for DSM-IV (SCID-I) [21]. A first psychotic
episode was defined as the first time a patient displayed
positive psychotic symptoms of delusions and/or halluci-
nations or marked disorganized behavior. Admission sta-
tus at first psychiatric hospitalization was defined as
involuntary if the patient refused to be admitted to the
unit and a judicial report was necessary.
Assessments
Upon first hospital admission (baseline), patients with FEP
symptoms were assessed using a protocol that included the
SCID-I, urine drug screens (including cannabis derivatives),
the Addiction Severity Index (ASI) (see Table 1), Positive
and Negative Symptoms Scale (PANSS) [22,23], Hamilton
Depression Rating Scale (HDRS-21) [24,25], Young Mania
Rating Scale (YMRS) [26], Phillips Premorbid Adjustment
scale [27], Global Assessment of Functioning (GAF) [28],
and Strauss-Carpenter prognostic scale [29]. The same
protocol was administered to all patients at 1, 2, 3, 4, 5 and
8 years follow-up. Some patients had further hospitaliza-
tions whereas others did not. During the 8-year follow-up
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and interviewed, and we reviewed their psychiatric and
medical history.
For each patient, relevant clinical and demographic
variables were collected, and use and abuse of cannabis
and other drugs was determined using information ob-
tained from the patient, key informant, medical record,
and drug screens. We determined whether cannabis or
other substances had been used, how often they had
been used, and when that use had occurred. Cannabis
use was defined as having taken cannabis at least once
in the month prior to admission, and at least 4 times in
the last year. Cannabis use, abuse and dependence were
defined according to DSM-IV, using SCID-I [21], and
the data derived from urine analyses and the ASI (see
Table 1). The same method was used to establish use,
abuse or dependence of other drugs and alcohol. The re-
search team members who determined drug use were
blind to the clinical ratings; they discussed any inconsist-
encies and selected the most reliable source. At every
year of follow-up, patients were also interviewed using
the SCID-I and ASI, and urine analyses were performed.
Evaluations were performed during clinical interviews
and pertained to the previous week. Interviews were
conducted by three psychiatrists (A. G-P., S.B. and P.V.)
who had good inter-rater reliability for SCID-I diagnoses
(kappa = 0.88), and for the scales used (PANSS, kappa =
0.80; GAF, kappa = 0.95; Phillips premorbid scale, kappa =
0.77; YMRS, kappa = 0.83; HDRS-21, kappa 0.79; and
Strauss–Carpenter, kappa = 0. 79).
Adherence was defined as the medication behavior of
the patient (i.e., whether or not they took their medication
regularly following medical advice). Patient adherence totreatment at baseline and during follow-up was evaluated
using the Morisky–Green test, a validated, self-report, 4-
item scale [30]. Patients answer yes (score = 0) or no
(score = 1) to the following questions: “Do you sometimes
forget to take your medicine?”, “Are you sometimes care-
less with the time you take your medicine?”, “When you
feel good, do you sometimes not take your medicine?”,
and “When you feel bad with the medicine, do you some-
times not take it?”. Patients with a score of 4 were consid-
ered as having ‘good’ adherence, while those with a score
between 0 and 3 were classified as having ‘bad’ adherence.
Previous studies have demonstrated the validity and use-
fulness of this self-report tool [30,31].
At each visit, the number of relapses since the previous
visit was recorded together with scores for GAF-evaluated
psychosocial functioning, Clinical Global Impression (CGI),
and the Strauss–Carpenter prognostic scale. The Strauss–
Carpenter subscales collected information on hospitaliza-
tions in the last 12 months, work, social activity, global
functioning and symptoms in the last month, with a lower
score indicating a worse patient status. The number of hos-
pitalizations and suicide attempts over the 8-year follow-up
was recorded. Additional information from clinical records,
psychiatrists, family informants, and staff observations was
obtained as necessary. Patients who could not be contacted
during the study period were considered lost to follow-up.
All patients received pharmacological treatment, mainly
atypical antipsychotics, with no bias regarding their canna-
bis use or not. After hospital discharge, patients received
standard care at their community mental health center,
which was usually one visit per month. Family interven-
tions and psychological support were provided if required.
Further care was prescribed as necessary, including hos-
pitalizations, which were independent of patient socio-
economic status. If immediate attention was needed, an
emergency room was available on a 24-hour basis.
Patient classification
Patients were classified as having voluntary or involun-
tary first admission to the psychiatric hospital (baseline).
Adherence to treatment at each visit was categorized as
‘good’ or ‘bad’ based on the Morisky–Green test scores,
and we present the data for adherence (good/bad) at the
baseline visit and at the 8-year visit. In addition, the
change in adherence over 8 years of follow-up was cate-
gorized as ‘always bad’, ‘always good’, ‘improved from bad
to good’, or ‘worsened from good to bad’. For this, we
considered the adherence rating (good/bad) at baseline
and at each visit from year 1 to year 8. Each patient’s
pattern of cannabis use over the 8-year follow-up period
was classified as: ‘stopped use’, ‘continued use’ (i.e., the
patient used cannabis before the baseline evaluation and
continued to use it throughout the follow-up period) or
‘never used’.
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Comparisons between the good and bad adherence groups
were made using bivariate analyses: Mann–Whitney U
tests for continuous variables and Chi-square tests for
categorical variables. A linear regression analysis was per-
formed to assess the relationship between adherence at the
8-year visit (good or bad) and cannabis use during follow-
up (stopped use or never use versus continued use).
A logistic regression model was used to analyze the as-
sociation between adherence at 8 years (bad versus good)
and basal clinical variables. Finally, a multiple logistic re-
gression model determined factors associated with the
change in adherence (always bad versus improved) during
8 years of follow-up; cannabis use (stopped use or never
use versus continued use) during the study and type of
hospitalization (involuntary versus voluntary) were both
included as independent variables in the model.
Data are presented as beta coefficients and odds ratios
(OR) with p values.
All data were analyzed using SPSS 21.0 version.
Results
Baseline characteristics
Of the 98 FEP patients who met the study inclusion cri-
teria, were enrolled at baseline, and included in the ana-
lysis, six died during follow-up.
The baseline characteristics of the study sample (Table 2)
show that admission status was voluntary for 42 (42.9%)
patients and involuntary for 56 (57.1%) patients. All pa-
tients with involuntary admission had bad adherence at
baseline (p < 0.001 versus good adherence).
Adherence was bad for 74.4% (73/98) of patients and
good for 25.5% (25/98) of patients at baseline, with few
significant differences in characteristics between the
good and bad adherence groups, except for family his-
tory of psychosis (Table 2). Patients with good adherence
at baseline had higher mean scores for GAF (p = 0.019)
and HDRS-21 (p = 0.017), and were more likely to have
voluntary admission (p < 0.001) than the bad adherence
group. The Strauss–Carpenter total score did not differ
between adherence groups at baseline.
The total sample had a high frequency of alcohol con-
sumption (95.9%), tobacco use (80.6%) and cannabis use
(52%). There was no significant difference between ad-
herence groups in these variables, except for a higher
consumption of alcohol in the bad adherence subgroup
(Table 2).
8-Year data
- Adherence (basal and at 8 years) and clinical and
functional variables at 8 years
The percentage of patients with good adherence increased
from 25.5% (25/98) at baseline to 51.1% (47/92) at the 8-
year visit. In the logistic regression model, adherence at8 years was not associated with any of the clinical
variables (PANSS, GAF, YMRS, HDRS, Phillips, Strauss‒
Carpenter) except for cannabis use during follow-up. Type
of first hospitalization (voluntary/involuntary) was not
associated with adherence at the 8-year visit (B = 0.456;
OR = 1.578; p = 0.314).
The bivariate analysis in Table 3 shows that patients
with good adherence at 8 years had better outcomes than
patients with bad adherence at 8 years, with a higher mean
GAF score at 8 years (p = 0.007), a lower YMRS score at
8 years (p = 0.013), a higher Strauss–Carpenter total score
at 8 years (p = 0.010), less hospitalization in the previous
year (p = 0.001), better working capacity (p = 0.007), fewer
symptoms in the previous month (p < 0.001), and better
global functioning in the previous year (p < 0.001). There
were no significant differences between patients with good
and bad adherence at 8 years for the PANSS scores
(Table 3).
- Associations between adherence at 8 years and substance
use
At 8 years (Table 3), the frequency of alcohol consump-
tion (56.5%), cannabis use (29.3%) and use of other
drugs (16.3%) had decreased from baseline (see Table 2).
Compared with the bad adherence group, a significantly
lower proportion of patients with good adherence at
8 years had alcohol consumption (p = 0.019), cannabis
use (p < 0.001), or use of other drugs (p < 0.001).
Of the patients with bad adherence at 8 years, 44.4%
(20/45) continued to use cannabis at 8 years, while only
12.8% (6/47) of patients with good adherence continued
using cannabis (Table 3).
- Change in adherence over 8 years: associations with type
of hospitalization and cannabis use
Table 4 shows that 70.0% (28/40) of patients with ‘always
bad’ adherence had involuntary admission at baseline, as
did 95.7% (22/23) of the patients with adherence that
‘improved from bad to good’ during the study.
As seen in Table 4, a high proportion of patients whose
adherence ‘improved from bad to good’ had either never
used cannabis (50%, 11/23) or stopped using it during the
study (38.9%, 9/23). Among the 40 patients with ‘always
bad’ adherence, 20 (50%) continued to use cannabis, while
16 (38.32%) never used cannabis. Only 4 patients (11.8%)
with ‘always bad’ adherence stopped using cannabis during
the study, and there was a high frequency of alcohol use
(75%) and other drug use (32.5%) in this subgroup.
In the multiple logistic regression, after controlling for
type of first admission, patients who never used or
stopped using cannabis during follow-up were more likely
to have improved adherence than patients who continued
using cannabis during the study (B = 2.174, OR = 8.794,
p = 0.011). Similarly, after controlling for cannabis use,
Table 2 Baseline characteristics of the total sample of FEP patients and by baseline adherence (good, bad)
Variable Total sample (N = 98) Bad adherence (n = 73) Good adherence (n = 25) p value
Gender, n (%) Chi2 = 0.003 (p = 0.954)
Male 71 (72.4) 53 (72.6) 18 (72.0)
Female 27 (27.6) 20 (27.4) 7 (28.0)
Age 29.8 ± 10.7 29.9 ± 10.2 30.7 ± 12.2 U = 762.5 (p = 0.858)
Civil status, n (%) Chi2 = 2.910 (p = 0.233)
Single 74 (75.5) 57 (78.1) 17 (68.0)
Married 17 (17.3) 10 (13.7) 7 (28.0)
Other 7 (7.2) 6 (8.2) 1 (4.0)
Family history, n (%) Chi2 = 6.036 (p = 0.014)
No 16 (16.3) 8 (10.9) 8 (32.0)
Yes 82 (83.7) 65 (89.1) 17 (68.0)
Diagnosis, n (%) Chi2 = 0.601 (p = 0.740)
Bipolar disorder & affective 33 (33.7) 23 (31.5) 10 (40.0)
Schizophrenia 39 (39.8) 30 (41.1) 9 (36.0)
Other 26 (26.5) 20 (27.4) 6 (24.0)
PANSS basal positivea 24.8 ± 6.9 25.0 ± 6.7 24.4 ± 8.0 U = 636.0 (p = 0.640)
PANSS basal negativea 18.9 ± 9.4 18.3 ± 9.1 20.5 ± 9.7 U = 598.0 (p = 0.395)
PANSS basal generala 42.2 ± 11.4 40.6 ± 10.4 47.7 ± 13.1 U = 598.0 (p = 0.395)
GAF basalb 55.5 ± 17.9 58.5 ± 16.2 69.2 ± 14.8 U = 152.5 (p = 0.019)
YMRS basal 25.4 ± 12.1 26.8 ± 12.4 21.6 ± 11.8 U = 494.5 (p = 0.059)
HDRS-21 basal 17.9 ± 8.4 16.4 ± 7.0 22.6 ± 10.9 U = 446.0 (p = 0.017)
Phillips total basalc 5.6 ± 3.0 5.9 ± 2.9 5.2 ± 3.5 U = 587.5 (p = 0.337)
Strauss total basalb 12.8 ± 3.9 12.5 ± 3.7 13.1 ± 4.5 U = 281.5 (p = 0.830)
Aggressiveness, n % yes [vs. no] 73 (74.5) 57 (78.1) 16 (64.0) Chi2 = 1.943 (p = 0.163)
Tobacco use, n (%) yes [vs. no] 79 (80.6) 61 (83.6) 18 (72.0) Chi2 = 1.593 (p = 0.207)
Alcohol use, n (%) yes [vs. no] 94 (95.9) 72 (98.6) 22 (88.0) Chi2 = 5.375 (p = 0.020)
Cannabis use, n (%) yes [vs. no] 51 (52.0) 40 (54.8) 11 (44.0) Chi2 = 0.869 (p = 0.351)
Other drugs use, n (%) yes [vs. no] 33 (33.7) 25 (34.2) 8 (32.0) Chi2 = 0.042 (p = 0.837)
Voluntary admission, n (%) Chi2 = 44.749 (p < 0.001)
No 56 (57.1) 56 (76.7) 0 (0)
Yes 42 (42.9) 17 (23.3) 25 (100)
Data are presented as mean ± SD or n (%).
Total n varies for the different variables due to missing data. The percentage given for each variable refers to the total n available for that variable.
P values are results of Chi-square (categorical variables) and Mann–Whitney U tests (continuous variables) for the comparison between groups with good versus
bad adherence.
Values in bold are significant at p < 0.05.
Note: PANSS, Positive and Negative Symptoms Scale; GAF, Global Assessment of Functioning; YMRS, Young Mania Rating Scale; HDRS-21, Hamilton Depression
Rating Scale, Phillips total; Phillips Premorbid adjustment scale total score; Strauss, Strauss-Carpenter prognostic scale score.
aFor PANSS scores, a higher score indicates worse symptoms.
bFor GAF and Strauss, a lower score indicates poorer functioning.
cFor Phillips, a higher score indicates poorer premorbid adjustment.
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to have improved adherence than patients who had volun-
tary admission (B = 1.731, OR = 5.645, p = 0.047).
Discussion
The two main findings of this study were that a longitu-
dinal improvement in adherence was associated withinvoluntary first admission and with quitting cannabis
use during follow-up in patients with recent psychotic
episodes. Our results suggest that cannabis use and its
withdrawal may be a mediator of adherence in FEP pa-
tients. However, the relationship could be bidirectional.
Our findings imply that efforts should be made to help
FEP patients quit cannabis use as this may improve their
Table 3 Clinical characteristics of total study sample at 8-year visit and by adherence at 8-year visit
Variable Total sample (N = 92) Bad adherence (n = 45) Good adherence (n = 47) p value
PANSS positive 24.8 ± 6.9 25.2 ± 7.8 24.4 ± 6.4 U = 607.0 (p = 0.413)
PANSS negative 18.9 ± 9.4 18.9 ± 9.4 20.0 ± 9.8 U = 652.5 (p = 0.745)
PANSS general 42.2 ± 11.4 44.0 ± 10.7 42.5 ± 11.9 U = 617.0 (p = 0.478)
YMRS 8 years 8.0 ± 9.2 12.0 ± 10.8 5.5 ± 7.2 U = 304.00 (p = 0.013)
Phillips 8 years 6.3 ± 2.9 6.9 ± 2.5 5.6 ± 3.0 U = 354.50 (p = 0.510)
GAF 8 years 61.3 ± 16.8 56.2 ±16.1 68.1 ± 15.9 U = 192.00 (p = 0.007)
Strauss 8 year total 12.8 ± 3.4 12.2 ± 4.6 15.2 ± 4.7 U = 189.5 (p = 0.010)
Strauss hospitalization, n (%) yes [vs. no] 35 (37.7) 25 (53.8) 10 (19.2) Chi2 = 11.461 (p = 0.001)
Strauss work, n (%) Chi2 = 9.809 (p = 0.007)
No 41 (44.6) 24 (53.3) 17 (36.2)
Partial 14 (15.2) 10 (22.2) 4 (8.5)
Total 37 (40.2) 11 (24.5) 26 (55.3)
Strauss social activity, n (%) Chi2 = 1.595 (p = 0.450)
No 14 (15.2) 7 (15.6) 7 (14.9)
Little contact 7 (7.6) 5 (11.1) 2 (4.2)
Frequently 71 (77.2) 33 (73.3) 38 (80.9)
Strauss symptoms, n (%) Chi2 = 25.641 (p < 0.001)
Severe 14 (15.2) 8 (17.8) 6 (12.8)
Moderate 20 (21.7) 18 (40.0) 2 (4.2)
Light 32 (34.8) 15 (33.3) 17 (36.2)
None 26 (28.3) 4 (8.9) 22 (46.8)
Strauss global functioning, n (%) Chi2 = 22.561 (p < 0.001)
Continued & severe 2 (2.2) 2 (4.4) 0 (0)
Important 11 (12.0) 6 (13.3) 5 (10.6)
Moderate 27 (29.3) 21 (46.7) 6 (12.8)
Light 30 (32.6) 13 (28.9) 17 (36.2)
No disorder 22 (23.9) 3 (6.7) 19 (40.4)
Alcohol use, n (%) yes [vs. no] 52 (56.5) 31 (68.9) 21 (44.7) Chi2 = 5.482 (p = 0.019)
Cannabis use, n (%) yes [vs. no] 27 (29.3) 21 (46.7) 6 (12.8) Chi2 = 12.742 (p < 0.001)
Other drugs use, n (%) yes [vs. no] 15 (16.3) 15 (33.3) 0 (0) Chi2 = 18.719 (p < 0.001)
Evolution of cannabis use, n (%) Chi2 = 11.436 (p = 0.003)
Stop use 25 (27.2) 9 (20.0) 16 (34.0)
Continue use 26 (28.3) 20 (44.4) 6 (12.8)
Never use 41 (44.5) 16 (35.6) 25 (53.2)
Data are presented as mean ± SD or n (%).
Total n varies for the different variables due to missing data. The percentage given for each variable refers to the total n available for that variable.
p values are results of Chi-square (categorical variables) and Mann–Whitney U tests (continuous variables) for the comparison between groups with good versus
bad adherence.
Values in bold are significant at p < 0.05.
Note: PANSS, Positive and Negative Symptoms Scale; GAF, Global Assessment of Functioning; YMRS, Young Mania Rating Scale; HDRS-21, Hamilton Depression
Rating Scale, Phillips total; Phillips Premorbid adjustment scale total score; Strauss, Strauss-Carpenter prognostic scale score.
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and functional outcomes. This could be especially im-
portant in patients with involuntary admissions.
At first hospitalization, 74.4% of our study sample had
bad adherence, which is consistent with previous reports
of FEP patients [1]. It has been shown that FEP patientscan provide a reasonable estimate of medication adher-
ence [32].
In our study, 57.1% of the FEP patients had involun-
tary first admission to the psychiatric unit and all of
these patients had bad adherence upon admission. This
high level of involuntary admission is consistent with










to good (n = 23)
Worsened from good
to bad (n = 5)
Voluntary admission
at baseline, n (%)a
54.289 (p < 0.001)
No 50 (54.3) 28 (70.0) 0 (0.0) 22 (95.7) 0 (0.0)
Yes 42 (45.7) 12 (30.0) 24 (100.0) 1 (4.3) 5 (100.0)
Evolution of cannabis
use, n (%)
24.036 (p = 0.001)
Stop use 23 (25.3) 4 (11.8) 6 (27.8) 9 (38.9) 4 (75.0)
Continue use 27 (29.1) 20 (50.0) 4 (11.1) 3 (11.1) 0 (0.0)
Never use 42 (45.6) 16 (38.2) 14 (61.1) 11 (50.0) 1 (25.0)
GAF at 8 years 55.5 ± 17.9 56.5 ± 16.0 73.4 ± 10.7 62.1 ± 17.0 53.7 ± 19.6 10.245 (p = 0.036)
aThe percentages of voluntary admission at baseline are different from those in Table 1 because they are calculated for 92 patients at 8 years (6 patients died
during follow-up).
Data are presented as mean ± SD or n (%). Total n varies for the different variables due to missing data. The percentage given for each variable refers to the total
n available for that variable.
p values are results of Chi-square tests (categorical variables) for the comparison between adherence groups. Values in bold are significant at p < 0.05.
Note: GAF, Global Assessment of Functioning.
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admissions for mental disorders have increased in recent
years [33,34]. An important finding of our study is that
treatment adherence improved from bad to good during
8 years of follow-up for 25% of the study sample, and
that almost all (96%) of these patients had been hospital-
ized involuntarily at baseline.
Involuntary admissions were associated with improved
adherence in the long term, and good adherence was as-
sociated with better functionality. Although they did not
measure the relationship between involuntary admission
and adherence, Priebe et al. [35] found that 40% of pa-
tients with involuntary first admission not only consid-
ered this therapeutic measure necessary but also these
patients had better prognosis.
Adherence was related to functionality at the 8-year
visit. The GAF mean scores show that patient functioning
was generally poor at baseline and did not improve during
follow-up. This is consistent with the Strauss–Carpenter
scale scores at 8 years, which showed that 44.6% of pa-
tients were not working, 37.7% had been hospitalized dur-
ing the previous year, and 15.2% had no social activity.
Patients with bad adherence at 8 years had worse func-
tionality than patients with good adherence at 8 years. In
our sample of FEP patients, cannabis use was high at base-
line (52% of patients), but fell to 29.3% at 8 years. Alcohol
consumption rates also decreased from 95.9% to 56.5%.
Our findings agree with other studies showing that FEP
patients often have multiple substance use initially, and
that about half of the patients stop or reduce cannabis use
during treatment [36].
Consistent with a previous longitudinal study [18], we
found a significant association between cannabis use andtreatment adherence in FEP patients during long-term
follow-up. The majority (20/27, 74%) of patients who
continued to use cannabis over the 8-year follow-up
period had consistently bad adherence, whereas only
17% (4/23) of the patients who stopped using cannabis
were in the always bad adherence group. We have previ-
ously reported that FEP patients who stopped using can-
nabis during 8 years of follow-up had better functional
outcomes and fewer negative symptoms than patients
who continued using cannabis or who had never used
cannabis [37]. Our present results extend this by show-
ing a relationship between long-term cannabis use, poor
functionality and the pattern of adherence. Likewise,
Schimmelmann et al. [36] demonstrated that FEP adoles-
cents who stopped using cannabis had better outcomes
(CGI-S, GAF, remission of positive symptoms) than those
who continued to use cannabis, although non-adherence
did not explain the association between persistent canna-
bis use and worse outcomes. Persistent substance abuse is
also a significant predictor of service disengagement
[38], adding to the growing evidence that reduction of
substance use should be a major focus of treatment in
FEP patients.
The adherence pattern over 8 years of follow-up was
associated with admission status at baseline (involun-
tary/voluntary) and the course of cannabis use over time,
while alcohol use at first hospitalization was associated
with baseline adherence, indicating that these variables
may be early predictors of adherence. Consistent with
this, Hill et al. [11] found that alcohol or substance mis-
use at inception predicted non-adherence at four years.
However, Weiss et al. [14] reported that substance use at
baseline did not predict future non-adherence, but the
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inpatients or first-episode patients, and that substance
use was mild and measured using a different scale.
Our study has several limitations. First, adherence was
measured by self-report and is, therefore, subject to re-
call bias and possibly overestimation. Additionally, ad-
herence was categorized as ‘bad’ or ‘good’, which is an
over simplification of such a complex phenomenon. Sec-
ond, the study sample was from the Vitoria region of
Spain and the results may not be generalizable to FEP
patients from other areas/regions. Another limitation is
that we only included hospitalized patients; therefore,
the findings are not applicable to FEP patients who do
not require hospital admission, which can be up to 20%
of patients [39]. Also, we examined the type of first hospital
admission (voluntary/involuntary) as a factor associated
with adherence, but did not consider the frequency of re-
admissions during follow-up, which may be an important
independent variable [40]. Moreover, we did not evaluate
the patient‒doctor relationship, which could be a major
factor influencing adherence [14]. Finally, our analyses
were for patients with 8 years of follow-up data. Patients
lost to follow-up may be non-adherent and have different
outcomes and associations from those who remained in
the study. Above all, as this study was not randomized, it is
important not to assume causal relationships.
Recently, Martinez-Ortega et al. [40] stressed the need
for prospective longitudinal investigations of the relation-
ship between clinical variables, socio-demographic factors
and voluntary/involuntary admission status of patients
with mental disorders. The main strengths of our study
are the prospective design and assessment of a consecu-
tive series of FEP inpatients from a geographically-defined
population over a long follow-up period of 8 years. Other
strengths are that we repeatedly measured adherence and
substance use at various time points during the study,
giving us a picture of how they changed over the course
of illness. We also used a wide range of standardized
measures to gather information on other variables that
may be involved.
Conclusions
This study confirms there is a high rate of cannabis use
among patients hospitalized with first-episode psychosis.
More importantly, it shows an association between canna-
bis use and treatment adherence over an 8 year period,
with better long-term adherence among patients who
never used cannabis or who stopped using it. Adherence
during follow-up is also better in patients with involuntary
first admission. Since almost all of the patients with im-
proved adherence over time had been admitted involuntar-
ily at baseline, and many of these patients quit using
cannabis, this shows the importance of involuntary admis-
sions in FEP. Our findings imply that FEP patients withcoexisting cannabis use are more likely to be non-adherent
to medication and should be a target for interventions
aimed at both stopping substance use and improving ad-
herence. Such efforts include involuntary admissions and
may result in improved clinical outcomes and patient func-
tioning although further studies are needed.
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